Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Detrimental effects of pretransplant cisplatin-based chemotherapy on renal function after allogeneic hematopoietic cell transplantation for lymphoma

Bone Marrow Transplantation volume 55, pages 2196–2198 (2020)Cite this article

Subjects

Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for patients with lymphoma whose disease is refractory to chemotherapy. Platinum derivatives such as carboplatin (CBDCA) and cisplatin (CDDP) play important roles in salvage chemotherapy for lymphoma [1,2,3,4,5,6], but may cause renal injury. Some salvage regimens include CDDP [1,2,3], while others include CBDCA or no platinum derivatives, which may help to reduce nephrotoxicity [4,5,6,7,8]. We hypothesized that pretransplant platinum-based chemotherapy may be associated with renal injury after allogeneic HCT for lymphoma.

The study cohort included 229 consecutive adult patients with lymphoma who had a first allogeneic HCT between 2000 and 2014 at the National Cancer Center Hospital. The estimated glomerular filtration rate (eGFR) was calculated as described previously [9]. Renal injury was defined as eGFR <60 ml/min/1.73 m2. Logistic regression models were used to examine factors associated with pretransplant renal injury. Covariates included cumulative dose of CBDCA and CDDP before HCT, patient age at HCT, patient sex, diagnosis, disease status at HCT, number of chemotherapy regimens before HCT, prior autologous HCT and performance status at HCT. In comparing changes in renal function over time between the groups, a within-group factor, a between-group factor, and statistical interaction were estimated using the repeated measures analysis of variance (ANOVA). This retrospective study was approved by the institutional review board of the National Cancer Center. The study was conducted in accordance with the Declaration of Helsinki.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Changes in mean eGFR across time after transplantation according to the cumulative platinum doses before transplantation.

References

  1. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117–22.

    Article  CAS  Google Scholar 

  2. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, et al. ESHAP–an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12:1169–76.

    Article  CAS  Google Scholar 

  3. Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer. 2004;101:1835–42.

    Article  CAS  Google Scholar 

  4. Okamoto M, Maruyama F, Tsuzuki M, Nomura T, Miyazaki H, Wakita M. et al. [Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin]. Rinsho Ketsueki. 1994;35:635–41.

    CAS  PubMed  Google Scholar 

  5. Gopal AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, Daniels JT, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma. 2010;51:1523–9.

    Article  CAS  Google Scholar 

  6. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3776–85.

    Article  CAS  Google Scholar 

  7. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000;18:3633–42.

    Article  CAS  Google Scholar 

  8. Ogura M, Kagami Y, Taji H, Suzuki R, Miura K, Takeuchi T, et al. Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma. Int J Hematol. 2003;77:503–11.

    Article  CAS  Google Scholar 

  9. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

    Article  CAS  Google Scholar 

  10. Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23:19–28.

    Article  Google Scholar 

  11. Tixier F, Ranchon F, Iltis A, Vantard N, Schwiertz V, Bachy E, et al. Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients. Hematol Oncol. 2017;35:584–90.

    Article  CAS  Google Scholar 

  12. Sorigue M, Sancho JM, Pineda A, Garcia O, Lopez D, Moreno M, et al. Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma. Leuk Res. 2017;58:98–101.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank patients, families, and staffs in the transplantation team of the National Cancer Center Hospital, Tokyo, Japan.

Funding

This study was supported by grants from the Japan Society for the Promotion of Science (18K08345), and the National Cancer Research and Development Fund (26-A-26).

Author information

Authors and Affiliations

  1. Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan

    Akio Onishi, Yoshihiro Inamoto, Kinuko Tajima, Junko Yamaguchi, Ichiro Kawashima, Akihisa Kawajiri, Tomonari Takemura, Ayumu Ito, Takashi Tanaka, Keiji Okinaka, Shigeo Fuji, Saiko Kurosawa, Sung-Won Kim & Takahiro Fukuda

Authors
  1. Akio Onishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihiro Inamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kinuko Tajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junko Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ichiro Kawashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akihisa Kawajiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomonari Takemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ayumu Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takashi Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Keiji Okinaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shigeo Fuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Saiko Kurosawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Sung-Won Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Takahiro Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AO and YI designed the study, collected and analyzed the data, performed statistical analyses and wrote the manuscript. KT performed statistical analyses and wrote the paper. JY, IK, AK, TT, AI, TT, KO, SF, SK, SWK, and TF collected data, reviewed, and approved the manuscript.

Corresponding author

Correspondence to Yoshihiro Inamoto.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Onishi, A., Inamoto, Y., Tajima, K. et al. Detrimental effects of pretransplant cisplatin-based chemotherapy on renal function after allogeneic hematopoietic cell transplantation for lymphoma. Bone Marrow Transplant 55, 2196–2198 (2020). https://doi.org/10.1038/s41409-020-0917-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-0917-2

This article is cited by

Search

Advanced search

Quick links